Pharmacological studies using sphingosine kinase inhibitors have shown no changes in the extent of atherosclerosis in LDL receptor-deficient mice (LDLR−/−) despite a reduction in plasma S1P concentrations [11]. Here, LDLR is linked to atherosclerosis.